Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

30 November 2017 : Laboratory Research  

MicroRNA-588 is downregulated and may have prognostic and functional roles in human breast cancer

Miao Yu1ABC, Xin Zhang1DE, Hui Li1BC, Purong Zhang1ABCD, Wei Dong12AFG*

DOI: 10.12659/MSM.905126

Med Sci Monit 2017; 23:5690-5696

Abstract

BACKGROUND: We explored the expression pattern, prognostic potential, and functional role of microRNA-588 (miR-588) in human breast cancer (BC).

MATERIAL AND METHODS: The expression pattern of miR-588 was assessed by qPCR in BC cell lines and human BC carcinomas. The correlations between miR-588 and BC patients’ clinicopathological characteristics, as well as BC patients’ overall survival, were statistically assessed. In in vitro culture, MCF-7 and MDA-MB-231 cells were infected with lentivirus to overexpress endogenous miR-588. The subsequent effects of miR-588 upregulation on BC cell proliferation and cisplatin chemosensitivity were examined.

RESULTS: miR-588 was found to be significantly downregulated in both BC cell lines and carcinoma tissues of BC patients. Low expression of miR-588 was closely correlated with BC patients’ poor prognosis of TNM stage, lymph node metastasis, and estrogen receptor status. In addition, patients with low miR-588-expressing carcinomas had much shorter overall survival. In MCF-7 and MDA-MB-231 cells, lentiviral infection induced significant miR-588 upregulation, and miR-588 upregulation had an anti-tumor effect in BC cells by significantly inhibiting cancer proliferation and increasing cisplatin chemosensitivity.

CONCLUSIONS: miR-588 is downregulated in BC and its aberrant expression is closely associated with patients’ poor prognosis and overall survival, thus suggesting a biomarker role. miR-588 also has anti-tumor function in BC, making it a potential therapeutic target for BC treatment.

Keywords: Carcinoma, Acinar Cell, Triple Negative Breast Neoplasms, Tumor Markers, Biological

Add Comment 0 Comments

Editorial

01 May 2024 : Editorial  

Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)

Dinah V. Parums

DOI: 10.12659/MSM.944927

Med Sci Monit 2024; 30:e944927

In Press

Animal Research  

Enhanced Bone Healing Through Systemic Capsaicin Administration: An Experimental Study on Wistar Rats

Med Sci Monit In Press; DOI: 10.12659/MSM.942485  

0:00

Clinical Research  

Differential Inflammatory Responses in Adult and Pediatric COVID-19 Patients: Implications for Long-Term Co...

Med Sci Monit In Press; DOI: 10.12659/MSM.944052  

Clinical Research  

Effectiveness of Shoulder Taping in Treating Hemiplegic Shoulder Subluxation: A Randomized Controlled Study...

Med Sci Monit In Press; DOI: 10.12659/MSM.944222  

Clinical Research  

Comparison of Fentanyl, Ketamine, and Lidocaine Combined with Propofol Anesthesia in Patients with Crohn Di...

Med Sci Monit In Press; DOI: 10.12659/MSM.944116  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750